EuBiologics Co., Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
A206650 Community Narratives
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
EuBiologics Co., Ltd. Key Details
About A206650
- Founded
- 2010
- Employees
- n/a
- CEO
- Website
View website
EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules. In addition, it offers carrier protein vaccine under the rCRM197 name; and biopharmaceutical contract research and manufacturing, and contract testing services. Further, the company engages in the development of and support for the manufacturing technologies of biomedicines. The company was founded in 2010 and is headquartered in Seoul, South Korea.